Table 2.5Emergency contraceptive pills (ECPs) (changes are highlighted in bold)

Emergency contraceptive pills (ECPs) (changes are highlighted in bold)

ConditionCOCLNGUPA
PregnancyNAaNAaNAa
Breastfeeding112a
Past ectopic pregnancy111
Obesity1a1a1a
History of severe cardiovascular disease (ischaemic heart disease, cerebrovascular attack, or other thromboembolic conditions)222
Migraine222
Severe liver disease (including jaundice)222
CYP3A4 inducers (e.g. rifampicin, phenytoin, phenobarbital, carbamazepine, efavirenz, fosphenytoin, nevirapine, oxcarbazepine, primidone, rifabutin, St John's wort/Hypericum perforatum)1a1a1a
Repeated ECP use1a1a1a
Rape111

COC: combined oral contraceptives; CYP3A4: cytochrome P450 3A4 enzyme; LNG: levonorgestrel; UPA: ulipristal acetate.

a

Please consult the relevant table for each contraceptive method in section 2.7 for a clarification to this classification.

From: II, Using the recommendations

Cover of Medical Eligibility Criteria for Contraceptive Use
Medical Eligibility Criteria for Contraceptive Use. 5th edition.
Copyright © World Health Organization 2015.

All rights reserved. Publications of the World Health Organization are available on the WHO website (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: tni.ohw@sredrokoob).

Requests for permission to reproduce or translate WHO publications –whether for sale or for non-commercial distribution– should be addressed to WHO Press through the WHO website (www.who.int/about/licensing/copyright_form/en/index.html).

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.